Sandoz gets European Commission nod for Hyrimoz high-concentration formulation Ruchika Sharma4 April 2023 2:00 PM ISTAdalimumab is a human immunoglobulin G1 (IgG(1)) monoclonal antibody targeting tumor necrosis factor alpha (TNF-a).
USFDA nod to citrate free high concentration formulation of biosimilar Hyrimoz injection: Sandoz Ruchika Sharma22 March 2023 1:45 PM ISTSandoz intends to launch the Hyrimoz citrate-free HCF in the US on July 1, 2023.
USFDA accepts Biologics License Application for proposed biosimilar denosumab: Sandoz Ruchika Sharma7 Feb 2023 10:15 AM ISTDenosumab is a human monoclonal antibody designed to bind to the RANKL protein, an activator of osteoclasts (cells involved in breaking down bone...
Novartis division Sandoz to set up Global Capability Centre in Hyderabad MD Bureau1 Feb 2023 1:30 PM ISTThe centre will initially have a workforce of 800 employees, with plans to increase to approximately 1,800 people in the near future.
Sandoz signs agreement to acquire antifungal agent Mycamine from Astellas Ruchika Sharma26 Jan 2023 11:30 AM ISTBasel: Sandoz has signed an agreement to acquire worldwide product rights for systemic antifungal agent Mycamine (micafungin sodium, Funguard in...
Patent infringement: Roche loses US appeal in Sandoz lung disease drug case Ruchika Sharma24 Dec 2022 11:30 AM ISTSan Francisco-based Genentech's Esbriet is used to treat IPF, a serious chronic lung disease. Roche earned over $1 billion last year from worldwide...
Sandoz, Teva Pharma plans to ramp up biosimilars production Ruchika Sharma23 Nov 2022 1:30 PM ISTTeva Chief Executive KÃ¥re Schultz said the company was targeting "80% of what's going off-patent in the next 10 years" including big sellers like the...
Novartis plans to shut down Sandoz North Carolina plant by 2023 end Ruchika Sharma12 Sept 2022 12:24 PM ISTZurich: Pharmaceuticals company Novartis plans to close a Sandoz generics plant in Wilson, North Carolina, around the end of 2023, it said on...
Novartis Sandoz division to go independent Ruchika Sharma25 Aug 2022 2:33 PM ISTThe standalone Sandoz would be headquartered in Switzerland and listed on the SIX Swiss Exchange, with an American Depositary Receipt (ADR) program in...
Sandoz Supplemental Biologics License application accepted by US FDA for biosimilar Hyrimoz high concentration formulation Ruchika Sharma24 July 2022 10:00 AM ISTAdalimumab is a human immunoglobulin G1 (IgG(1)) monoclonal antibody targeting tumor necrosis factor alpha (TNF-a).
Novartis division Sandoz inaugurates facility in Maharashtra for oral cancer medicines Ruchika Sharma1 July 2022 1:30 PM ISTThe plant, which is spread over 32,000 square metres, would cater to the export markets, it added.
Novartis division Sandoz application for proposed biosimilar Hyrimoz's high concentration formulation accepted by EMA Ruchika Sharma19 Jun 2022 11:30 AM ISTUpon approval, the Hyrimoz (100 mg/mL) citrate-free HCF would offer reduced injection volume and potentially decrease the number of injections...
